TRPV1: A therapy target that attracts the pharmaceutical interests

Advances in Experimental Medicine and Biology

Volumn 704, Issue , 2011, Pages 637-665

  Xia, Rong ^a   Dekermendjian, Kim ^b   Lullau, Elke ^a   Dekker, Niek ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Drugability; Nociception; Pain; Pharmacology; TRPV1

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; 1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; 4 [3 (TRIFLUOROMETHYL) 2 PYRIDINYL] N [5 (TRIFLUOROMETHYL) 2 PYRIDINYL] 1 PIPERAZINECARBOXAMIDE; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; 705498; ALGX 4975; AZD 1386; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; CAPSAICIN; CAPSAZEPINE; CIS CAPSAICIN; CIVAMIDE CREAM; CIVAMIDE NASAL SOLUTION; GRC 6211; JTS 653; LIGAND; MK 2295; MONOCLONAL ANTIBODY; N (1,4 BENZODIOXAN 6 YL) 3 (4 TERT BUTYLPHENYL)ACRYLAMIDE; N (4 TERT BUTYLPHENYL) 4 (3 CHLORO 2 PYRIDINYL) 1 PIPERAZINECARBOXAMIDE; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; PLACEBO; POLYCLONAL ANTIBODY; QUINAZOLINONE DERIVATIVE; SB 336791; TRANSIENT RECEPTOR POTENTIAL CHANNEL V1 AGONIST; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

ANALGESIC ACTIVITY; BINDING ASSAY; BINDING SITE; BLADDER; BODY TEMPERATURE; CALCIUM TRANSPORT; CANCER PAIN; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CHANNEL GATING; COLD SENSATION; CONFERENCE PAPER; COUGHING; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; FLUORESCENCE ANALYSIS; HEADACHE; HUMAN; HYDROPHOBICITY; HYPERALGESIA; HYPERTHERMIA; ION PERMEABILITY; IRRITABLE COLON; MECHANICAL HYPERALGESIA; MIGRAINE; NEURALGIA; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; OVERACTIVE BLADDER; PAIN; PATCH CLAMP; POSTHERPETIC NEURALGIA; POSTTRAUMATIC NEURALGIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; RECEPTOR DOWN REGULATION; RECTAL HYPERSENSITIVITY; RECTUM DISEASE; RENOVASCULAR HYPERTENSION; REPEATED DRUG DOSE; RESPIRATORY SYSTEM; RHINITIS; SHIVERING; SIDE EFFECT; SINGLE DRUG DOSE; SPINAL GANGLION; TEMPERATURE SENSE; THERMAL HYPERALGESIA; TISSUE DISTRIBUTION; TOOTH EXTRACTION; TOOTH PAIN; CRYOELECTRON MICROSCOPY; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN CONFORMATION; REVIEW; ULTRASTRUCTURE;

CRYOELECTRON MICROSCOPY; HUMANS; PAIN; PROTEIN CONFORMATION; TRPV CATION CHANNELS;

EID: 79959808567     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-0265-3_34     Document Type: Conference Paper

References (172)

1. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 389:816-824
2. Cortright DN, Krause JE, Broom DC (2007) TRP channels and pain. Biochim Biophys Acta 1772:978-988
3. Breese NM, George AC, Pauers LE, Stucky CL (2005) Peripheral inflammation selectively increases TRPV1 function in IB4-positive sensory neurons from adult mouse. Pain 115: 37-49
4. Latorre R, Brauchi S, Orta G, Zaelzer C, Vargas G (2007) Thermo TRP channels as modular proteins with allosteric gating. Cell Calcium 42:427-438
5. Caterina MJ, Julius D (2001) The vanilloid receptor: A molecular gateway to the pain pathway. Annu Rev Neurosci 24:487-517
6. Kedei N, Szabo T, Lile JD, Treanor JJ, Olah Z, Iadarola MJ, Blumberg PM (2001) Analysis of the native quaternary structure of vanilloid receptor 1. J Biol Chem 276:28613-28619
7. Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, McIntyre P (2003) The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 304:56-62
8. Chanda S, Sharper V, Hoberman A, Bley K (2006) Developmental toxicity study of pure trans-capsaicin in rats and rabbits. Int J Toxicol 25:205-217
9. Correll CC, Phelps PT, Anthes JC, Umland S, Greenfeder S (2004) Cloning and pharmacological characterization of mouse TRPV1. Neurosci Lett 370:55-60
10. Zimov S, Yazulla S (2004) Localization of vanilloid receptor 1 (TRPV1/VR1)-like immunoreactivity in goldfish and zebrafish retinas: Restriction to photoreceptor synaptic ribbons. J Neurocytol 33:441-452
11. Ohta T, Komatsu R, Imagawa T, Otsuguro K, Ito S (2005) Molecular cloning, functional characterization of the porcine transient receptor potential V1 (pTRPV1) and pharmacological comparison with endogenous pTRPV1. Biochem Pharmacol 71:173-187
12. Lu G, Henderson D, Liu L, Reinhart PH, Simon SA (2005) TRPV1b, a functional human vanilloid receptor splice variant. Mol Pharmacol 67:1119-1127
13. Vos MH, Neelands TR, McDonald HA, Choi W, Kroeger PE, Puttfarcken PS, Faltynek CR, Moreland RB, Han P (2006) TRPV1b overexpression negatively regulates TRPV1 responsiveness to capsaicin, heat and low pH in HEK293 cells. J Neurochem 99:1088-1102
14. Sharif Naeini R, Witty MF, Seguela P, Bourque CW (2006) An N-terminal variant of Trpv1 channel is required for osmosensory transduction. Nat Neurosci 9:93-98
15. Lyall V, Heck GL, Vinnikova AK, Ghosh S, Phan TH, Alam RI, Russell OF, Malik SA, Bigbee JW, DeSimone JA (2004) The mammalian amiloride-insensitive non-specific salt taste receptor is a vanilloid receptor-1 variant. J Physiol 558:147-159
16. Lyall V, Phan TH, Mummalaneni S, Melone P, Mahavadi S, Murthy KS, DeSimone JA (2009) Regulation of the benzamil-insensitive salt taste receptor by intracellular Ca2+, protein kinase C, and calcineurin. J Neurophysiol 102:1591-1605
17. Moiseenkova-Bell VY, Stanciu LA, Serysheva II, Tobe BJ, Wensel TG (2008) Structure of TRPV1 channel revealed by electron cryomicroscopy. Proc Natl Acad Sci USA 105: 7451-7455
18. Gouaux E (1998) Single potassium ion seeks open channel for transmembrane travels: Tales from the KcsA structure. Structure 6:1221-1226
19. Long SB, Campbell EB, Mackinnon R (2005) Crystal structure of a mammalian voltagedependent Shaker family K+ channel. Science 309:897-903
20. Garcia-Martinez C, Morenilla-Palao C, Planells-Cases R, Merino JM, Ferrer-Montiel A (2000) Identification of an aspartic residue in the P-loop of the vanilloid receptor that modulates pore properties. J Biol Chem 275:32552-32558
21. Venkatachalam K, Montell C (2007) TRP channels. Annu Rev Biochem 76:387-417
22. Pedersen SF, Owsianik G, Nilius B (2005) TRP channels: An overview. Cell Calcium 38:233-252
23. Montell C (2005) The TRP superfamily of cation channels. Sci STKE 2005:re3
24. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS (2002) Gereau RWt: CAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 35:721-731
25. Schindl R, Frischauf I, Kahr H, Fritsch R, Krenn M, Derndl A, Vales E, Muik M, Derler I, Groschner K, Romanin C (2008) The first ankyrin-like repeat is the minimum indispensable key structure for functional assembly of homo- and heteromeric TRPC4/TRPC5 channels. Cell Calcium 43:260-269
26. Garcia-Sanz N, Fernandez-Carvajal A, Morenilla-Palao C, Planells-Cases R, Fajardo- Sanchez E, Fernandez-Ballester G, Ferrer-Montiel A (2004) Identification of a tetramerization domain in the C terminus of the vanilloid receptor. J Neurosci 24:5307-5314
27. Numazaki M, Tominaga T, Toyooka H, Tominaga M (2002) Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. J Biol Chem 277:13375-13378
28. Numazaki M, Tominaga T, Takeuchi K, Murayama N, Toyooka H, Tominaga M (2003) Structural determinant of TRPV1 desensitization interacts with calmodulin. Proc Natl Acad Sci USA 100:8002-8006
29. Bhave G, Hu HJ, Glauner KS, Zhu W, Wang H, Brasier DJ, Oxford GS (2003) Gereau RWt: Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci USA 100:12480-12485
30. Prescott ED, Julius D (2003) A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science 300:1284-1288
31. Sanchez JF, Krause JE, Cortright DN (2001) The distribution and regulation of vanilloid receptor VR1 and VR1 5 splice variant RNA expression in rat. Neuroscience 107:373-381
32. Wisnoskey BJ, Sinkins WG, Schilling WP (2003) Activation of vanilloid receptor type I in the endoplasmic reticulum fails to activate store-operated Ca2+ entry. Biochem J 372: 517-528
33. Southall MD, Li T, Gharibova LS, Pei Y, Nicol GD, Travers JB (2003) Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J Pharmacol Exp Ther 304:217-222
34. Liu B, Hui K, Qin F (2003) Thermodynamics of heat activation of single capsaicin ion channels VR1. Biophys J 85:2988-3006
35. Birder LA (2001) Involvement of the urinary bladder urothelium in signaling in the lower urinary tract. Proc West Pharmacol Soc 44:85-86
36. Daly D, Rong W, Chess-Williams R, Chapple C, Grundy D (2007) Bladder afferent sensitivity in wild-type and TRPV1 knockout mice. J Physiol 583:663-674
37. Avraham Y, Zolotarev O, Grigoriadis NC, Poutahidis T, Magen I, Vorobiav L, Zimmer A, Ilan Y, Mechoulam R, Berry EM (2008) Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice. Am J Gastroenterol 103:3047-3056
38. Zhang L, Taylor N, Xie Y, Ford R, Johnson J, Paulsen JE, Bates B (2005) Cloning and expression of MRG receptors in macaque, mouse, and human. Brain Res Mol Brain Res 133:187-197
39. Reilly CA, Taylor JL, Lanza DL, Carr BA, Crouch DJ, Yost GS (2003) Capsaicinoids cause inflammation and epithelial cell death through activation of vanilloid receptors. Toxicol Sci 73:170-181
40. Watanabe N, Horie S, Michael GJ, Spina D, Page CP, Priestley JV (2005) Immunohistochemical localization of vanilloid receptor subtype 1 (TRPV1) in the guinea pig respiratory system. Pulm Pharmacol Ther 18:187-197
41. Zhang X, Huang J, McNaughton PA (2005) NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 24:4211-4223
42. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ (2002) p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36:57-68
43. Lainez S, Valente P, Ontoria-Oviedo I, Estevez-Herrera J, Camprubi-Robles M, Ferrer- Montiel A, Planells-Cases R (2010) GABAA receptor associated protein (GABARAP) modulates TRPV1 expression and channel function and desensitization. Faseb J 24(6):1958- 1970
44. Jeske NA, Patwardhan AM, Henry MA, Milam SB (2009) Fibronectin stimulates TRPV1 translocation in primary sensory neurons. J Neurochem 108:591-600
45. Lee YM, Li WH, Kim YK, Kim KH, Chung JH (2008) Heat-induced MMP-1 expression is mediated by TRPV1 through PKCalpha signaling in HaCaT cells. Exp Dermatol 17:864-870
46. Amaya F, Wang H, Costigan M, Allchorne AJ, Hatcher JP, Egerton J, Stean T, Morisset V, Grose D, Gunthorpe MJ, Chessell IP, Tate S, Green PJ, Woolf CJ (2006) The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci 26:12852-12860
47. Rashid MH, Inoue M, Bakoshi S, Ueda H (2003) Increased expression of vanilloid receptor 1 on myelinated primary afferent neurons contributes to the antihyperalgesic effect of capsaicin cream in diabetic neuropathic pain in mice. J Pharmacol Exp Ther 306:709-717
48. Kamei J, Zushida K, Morita K, Sasaki M, Tanaka S (2001) Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice. Eur J Pharmacol 422:83-86
49. Hong S, Wiley JW (2005) Early painful diabetic neuropathy is associated with differential changes in the expression and function of vanilloid receptor 1. J Biol Chem 280:618-627
50. Hudson LJ, Bevan S, Wotherspoon G, Gentry C, Fox A, Winter J (2001) VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur J Neurosci 13:2105-2114
51. Kanai Y, Nakazato E, Fujiuchi A, Hara T, Imai A (2005) Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology 49:977-984
52. Ghilardi JR, Rohrich H, Lindsay TH, Sevcik MA, Schwei MJ, Kubota K, Halvorson KG, Poblete J, Chaplan SR, Dubin AE, Carruthers NI, Swanson D, Kuskowski M, Flores CM, Julius D, Mantyh PW (2005) Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25:3126-3131
53. Engler A, Aeschlimann A, Simmen BR, Michel BA, Gay RE, Gay S, Sprott H (2007) Expression of transient receptor potential vanilloid 1 (TRPV1) in synovial fibroblasts from patients with osteoarthritis and rheumatoid arthritis. Biochem Biophys Res Commun 359:884-888
54. Fernihough J, Gentry C, Bevan S, Winter J (2005) Regulation of calcitonin gene-related peptide and TRPV1 in a rat model of osteoarthritis. Neurosci Lett 388:75-80
55. Groneberg DA, Niimi A, Dinh QT, Cosio B, Hew M, Fischer A, Chung KF (2004) Increased expression of transient receptor potential vanilloid-1 in airway nerves of chronic cough. Am J Respir Crit Care Med 170:1276-1280
56. Chan CL, Facer P, Davis JB, Smith GD, Egerton J, Bountra C,Williams NS, Anand P (2003) Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 361:385-391
57. Banerjee B, Medda BK, Lazarova Z, Bansal N, Shaker R, Sengupta JN (2007) Effect of reflux-induced inflammation on transient receptor potential vanilloid one (TRPV1) expression in primary sensory neurons innervating the oesophagus of rats. Neurogastroenterol Motil 19:681-691
58. Matthews PJ, Aziz Q, Facer P, Davis JB, Thompson DG, Anand P (2004) Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 16:897-902
59. Charrua A, Cruz CD, Cruz F, Avelino A (2007) Transient receptor potential vanilloid subfamily 1 is essential for the generation of noxious bladder input and bladder overactivity in cystitis. J Urol 177:1537-1541
60. Wang ZY, Wang P, Merriam FV, Bjorling DE (2008) Lack of TRPV1 inhibits cystitisinduced increased mechanical sensitivity in mice. Pain 139:158-167
61. Dinis P, Charrua A, Avelino A, Yaqoob M, Bevan S, Nagy I, Cruz F (2004) Anandamideevoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci 24:11253-11263
62. Jia Y, Lee LY (2007) Role of TRPV receptors in respiratory diseases. Biochim Biophys Acta 1772:915-927
63. Watanabe N, Horie S, Michael GJ, Keir S, Spina D, Page CP, Priestley JV (2006) Immunohistochemical co-localization of transient receptor potential vanilloid (TRPV)1 and sensory neuropeptides in the guinea-pig respiratory system. Neuroscience 141: 1533-1543
64. Jia Y,McLeod RL, Hey JA (2005) TRPV1 receptor: A target for the treatment of pain, cough, airway disease and urinary incontinence. Drug News Perspect 18:165-171
65. Wang Y, Babankova D, Huang J, Swain GM,Wang DH (2008) Deletion of transient receptor potential vanilloid type 1 receptors exaggerates renal damage in deoxycorticosterone acetatesalt hypertension. Hypertension 52:264-270
66. Wimalawansa SJ (1996) Calcitonin gene-related peptide and its receptors: Molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 17: 533-585
67. Woudenberg-Vrenken TE, Bindels RJ, Hoenderop JG (2009) The role of transient receptor potential channels in kidney disease. Nat Rev Nephrol 5:441-449
68. Kopp UC, Cicha MZ, Smith LA (2003) Dietary sodium loading increases arterial pressure in afferent renal-denervated rats. Hypertension 42:968-973
69. Wang Y, Wang DH (2006) A novel mechanism contributing to development of Dahl saltsensitive hypertension: Role of the transient receptor potential vanilloid type 1. Hypertension 47:609-614
70. Koomans HA, Blankestijn PJ, Joles JA (2004) Sympathetic hyperactivity in chronic renal failure: A wake-up call. J Am Soc Nephrol 15:524-537
71. Charrua A, Reguenga C, Cordeiro JM, Correiade-Sa P, Paule C, Nagy I, Cruz F, Avelino A (2009) Functional transient receptor potential vanilloid 1 is expressed in human urothelial cells. J Urol 182:2944-2950
72. Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, Wang E, Ruiz G, De Groat WC, Apodaca G, Watkins S, Caterina MJ (2002) Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 5:856-860
73. Cefalu JS, Guillon MA, Burbach LR, Zhu QM, Hu DQ, Ho MJ, Ford AP, Nunn PA, Cockayne DA (2009) Selective pharmacological blockade of the TRPV1 receptor suppresses sensory reflexes of the rodent bladder. J Urol 182:776-785
74. Birder LA (2007) TRPs in bladder diseases. Biochim Biophys Acta 1772:879-884
75. Sadananda P, Shang F, Liu L, Mansfield KJ, Burcher E (2009) Release of ATP from rat urinary bladder mucosa: Role of acid, vanilloids and stretch. Br J Pharmacol 158: 1655-1662
76. Babes A, Amuzescu B, Krause U, Scholz A, Flonta ML, Reid G (2002) Cooling inhibits capsaicin-induced currents in cultured rat dorsal root ganglion neurones. Neurosci Lett 317:131-134
77. Romanovsky AA, Almeida MC, Garami A, Steiner AA, Norman MH, Morrison SF, Nakamura K, Burmeister JJ, Nucci TB (2009) The transient receptor potential vanilloid-1 channel in thermoregulation: A thermosensor it is not. Pharmacol Rev 61:228-261
78. Nilius B, Talavera K, Owsianik G, Prenen J, Droogmans G, Voets T (2005) Gating of TRP channels: A voltage connection?. J Physiol 567:35-44
79. Pingle SC, Matta JA, Ahern GP (2007) Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol 179:155-171
80. Vyklicky L, Lyfenko A, Kuffler DP, Vlachova V (2003) Vanilloid receptor TRPV1 is not activated by vanilloids applied intracellularly. NeuroReport 14:1061-1065
81. Woo DH, Jung SJ, Zhu MH, Park CK, Kim YH, Oh SB, Lee CJ (2008) Direct activation of transient receptor potential vanilloid 1(TRPV1) by diacylglycerol (DAG. Mol Pain 4:42
82. Sutton KG, Garrett EM, Rutter AR, Bonnert TP, Jarolimek W, Seabrook GR (2005) Functional characterisation of the S512Y mutant vanilloid human TRPV1 receptor. Br J Pharmacol 146:702-711
83. Premkumar LS, Agarwal S, Steffen D (2002) Single-channel properties of native and cloned rat vanilloid receptors. J Physiol 545:107-117
84. Holzer P (2009) Acid-sensitive ion channels and receptors. Handb Exp Pharmacol 194: 283-332
85. Jordt SE, Tominaga M, Julius D (2000) Acid potentiation of the capsaicin receptor determined by a key extracellular site. Proc Natl Acad Sci USA 97:8134-8139
86. Gavva NR, Tamir R, Klionsky L, Norman MH, Louis JC,Wild KD, Treanor JJ (2005) Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. Mol Pharmacol 68:1524-1533
87. Tousova K, Vyklicky L, Susankova K, Benedikt J, Vlachova V (2005) Gadolinium activates and sensitizes the vanilloid receptor TRPV1 through the external protonation sites. Mol Cell Neurosci 30:207-217
88. Ahern GP, Brooks IM, Miyares RL, Wang XB (2005) Extracellular cations sensitize and gate capsaicin receptor TRPV1 modulating pain signaling. J Neurosci 25:5109-5116
89. Raisinghani M, Pabbidi RM, Premkumar LS (2005) Activation of transient receptor potential vanilloid 1 (TRPV1) by resiniferatoxin. J Physiol 567:771-786
90. Ahern GP, Wang X, Miyares RL (2006) Polyamines are potent ligands for the capsaicin receptor TRPV1. J Biol Chem 281:8991-8995
91. Valente P, Garcia-Sanz N, Gomis A, Fernandez-Carvajal A, Fernandez-Ballester G, Viana F, Belmonte C, Ferrer-Montiel A (2008) Identification of molecular determinants of channel gating in the transient receptor potential box of vanilloid receptor I. FASEB J 22:3298-3309
92. Owsianik G, Talavera K, Voets T, Nilius B (2006) Permeation and selectivity of TRP channels. Annu Rev Physiol 68:685-717
93. Hellwig N, Plant TD, Janson W, Schafer M, Schultz G, Schaefer M (2004) TRPV1 acts as proton channel to induce acidification in nociceptive neurons. J Biol Chem 279: 34553-34561
94. Voets T, Janssens A, Droogmans G, Nilius B (2004) Outer pore architecture of a Ca2+- selective TRP channel. J Biol Chem 279:15223-15230
95. Voets T, Nilius B (2003) The pore of TRP channels: Trivial or neglected?. Cell Calcium 33:299-302
96. Voets T, Prenen J, Fleig A, Vennekens R, Watanabe H, Hoenderop JG, Bindels RJ, Droogmans G, Penner R, Nilius B (2001) CaT1 and the calcium release-activated calcium channel manifest distinct pore properties. J Biol Chem 276:47767-47770
97. Xia R, Mei ZZ, Mao HJ, Yang W, Dong L, Bradley H, Beech DJ, Jiang LH (2008) Identification of pore residues engaged in determining divalent cationic permeation in transient receptor potential melastatin subtype channel 2. J Biol Chem 283: 27426-27432
98. Voets T, Prenen J, Vriens J, Watanabe H, Janssens A, Wissenbach U, Bodding M, Droogmans G, Nilius B (2002) Molecular determinants of permeation through the cation channel TRPV4. J Biol Chem 277:33704-33710
99. Mohapatra DP, Nau C (2003) Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J Biol Chem 278:50080-50090
100. Chung MK, Guler AD, Caterina MJ (2008) TRPV1 shows dynamic ionic selectivity during agonist stimulation. Nat Neurosci 11:555-564
101. Mohapatra DP, Nau C (2005) Regulation of Ca2+-dependent desensitization in the vanilloid receptor TRPV1 by calcineurin and cAMP-dependent protein kinase. J Biol Chem 280:13424-13432
102. Mandadi S, Tominaga T, Numazaki M, Murayama N, Saito N, Armati PJ, Roufogalis BD, Tominaga M (2006) Increased sensitivity of desensitized TRPV1 by PMA occurs through PKCepsilon-mediated phosphorylation at S800. Pain 123:106-116
103. Jung J, Shin JS, Lee SY, Hwang SW, Koo J, Cho H, Oh U (2004) Phosphorylation of vanilloid receptor 1 by Ca2+/calmodulin-dependent kinase II regulates its vanilloid binding. J Biol Chem 279:7048-7054
104. Novakova-Tousova K, Vyklicky L, Susankova K, Benedikt J, Samad A, Teisinger J, Vlachova V (2007) Functional changes in the vanilloid receptor subtype 1 channel during and after acute desensitization. Neuroscience 149:144-154
105. Jahnel R, Bender O, Munter LM, Dreger M, Gillen C, Hucho F (2003) Dual expression of mouse and rat VRL-1 in the dorsal root ganglion derived cell line F-11 and biochemical analysis of VRL-1 after heterologous expression. Eur J Biochem 270:4264-4271
106. Korepanova A, Pereda-Lopez A, Solomon LR, Walter KA, Lake MR, Bianchi BR, McDonald HA, Neelands TR, Shen J, Matayoshi ED, Moreland RB, Chiu ML (2009) Expression and purification of human TRPV1 in baculovirus-infected insect cells for structural studies. Protein Expr Purif 65:38-50
107. Caterina MJ, Rosen TA, Tominaga M, Brake AJ, Julius D (1999) A capsaicin-receptor homologue with a high threshold for noxious heat. Nature 398:436-441
108. Bylund DB, Deupree JD, Toews ML (2004) Radioligand-binding methods for membrane preparations and intact cells. Methods Mol Biol 259:1-28
109. Salazar H, Llorente I, Jara-Oseguera A, Garcia-Villegas R, Munari M, Gordon SE, Islas LD, Rosenbaum T (2008) A single N-terminal cysteine in TRPV1 determines activation by pungent compounds from onion and garlic. Nat Neurosci 11:255-261
110. Dabrowski M (2009) Novel approaches in ion channel lead generation. In: Biophysical Society 53rd Annual Meeting, Boston, MA
111. Nanion Application Notes (2009) http://www.nanion.de/pdf/Patchliner- TRPV1.pdf
112. Smart D, Jerman JC, Gunthorpe MJ, Brough SJ, Ranson J, Cairns W, Hayes PD, Randall AD, Davis JB (2001) Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology. Eur J Pharmacol 417:51-58
113. Schroeder KS, Neagle BD (1996) FLIPR: A new instrument for accurate, high throughput optical screening. J Biomol Screen 1:5
114. Reubish D, Emerling D, Defalco J, Steiger D, Victoria C, Vincent F (2009) Functional assessment of temperature-gated ion-channel activity using a real-time PCR machine. Biotechniques 47:iii-ix
115. Kym PR, Kort ME, Hutchins CW (2009) Analgesic potential of TRPV1 antagonists. Biochem Pharmacol 78:211-216
116. Vriens J, Appendino G, Nilius B (2009) Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 75:1262-1279
117. Appendino G, Minassi A, Pagani A, Ech-Chahad A (2008) The role of natural products in the ligand deorphanization of TRP channels. Curr Pharm Des 14:2-17
118. Ahern GP (2003) Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem 278:30429-30434
119. Wang X, Miyares RL, Ahern GP (2005) Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J Physiol 564:541-547
120. Hwang SW, Oh U (2002) Hot channels in airways: Pharmacology of the vanilloid receptor. Curr Opin Pharmacol 2:235-242
121. Szallasi A, Appendino G (2004) Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse?. J Med Chem 47:2717-2723
122. McNamara FN, Randall A, Gunthorpe MJ (2005) Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1. Br J Pharmacol 144:781-790
123. Xu H, Blair NT, Clapham DE (2005) Camphor activates and strongly desensitizes the transient receptor potential vanilloid subtype 1 channel in a vanilloid-independent mechanism. J Neurosci 25:8924-8937
124. Siemens J, Zhou S, Piskorowski R, Nikai T, Lumpkin EA, Basbaum AI, King D, Julius D (2006) Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature 444:208-212
125. Dray A, Bettaney J, Forster P (1990) Resiniferatoxin, a potent capsaicin-like stimulator of peripheral nociceptors in the neonatal rat tail in vitro. Br J Pharmacol 99:323-326
126. Docherty RJ, Yeats JC, Piper AS (1997) Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture. Br J Pharmacol 121: 1461-1467
127. Liu L, Simon SA (1997) Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia. Neurosci Lett 228:29-32
128. Pal M, Angaru S, Kodimuthali A, Dhingra N (2009) Vanilloid receptor antagonists: Emerging class of novel anti-inflammatory agents for pain management. Curr Pharm Des 15: 1008-1026
129. Gharat LA (2008) Szallasi, Arpad: Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonists. Expert Opin Ther Pat 18:10
130. Rami HK, Thompson M, Stemp G, Fell S, Jerman JC, Stevens AJ, Smart D, Sargent B, Sanderson D, Randall AD, Gunthorpe MJ, Davis JB (2006) Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 16:3287-3291
131. Chizh BA, O'Donnell MB, Napolitano A, Wang J, Brooke AC, Aylott MC, Bullman JN, Gray EJ, Lai RY, Williams PM, Appleby JM (2007) The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 132:132-141
132. Honore P,Wismer CT, Mikusa J, Zhu CZ, Zhong C, Gauvin DM, Gomtsyan A, El Kouhen R, Lee CH, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF (2005) A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 314:410-421
133. El Kouhen R, Surowy CS, Bianchi BR, Neelands TR, McDonald HA, Niforatos W, Gomtsyan A, Lee CH, Honore P, Sullivan JP, Jarvis MF, Faltynek CR (2005) A-425619 [1- isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Ther 314:400-409
134. McGaraughty S, Chu KL, Faltynek CR, Jarvis MF (2006) Systemic and site-specific effects of A-425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats. J Neurophysiol 95:18-25
135. Surowy CS, Neelands TR, Bianchi BR, McGaraughty S, El Kouhen R, Han P, Chu KL, McDonald HA, Vos M, Niforatos W, Bayburt EK, Gomtsyan A, Lee CH, Honore P, Sullivan JP, Jarvis MF, Faltynek CR (2008) R)-(5-tert-butyl-2,3-dihydro-1H- inden-1-yl)- 3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo. J Pharmacol Exp Ther 326:879-888
136. Gomtsyan A, Bayburt EK, Schmidt RG, Surowy CS, Honore P, Marsh KC, Hannick SM, McDonald HA, Wetter JM, Sullivan JP, Jarvis MF, Faltynek CR, Lee CH (2008) Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H- indazol- 4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management. J Med Chem 51:392-395
137. Valenzano KJ, Grant ER, Wu G, Hachicha M, Schmid L, Tafesse L, Sun Q, Rotshteyn Y, Francis J, Limberis J, Malik S, Whittemore ER, Hodges D (2003) N-4-tertiarybutylphenyl)- 4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties. J Pharmacol Exp Ther 306:377-386
138. Pomonis JD, Harrison JE, Mark L, Bristol DR, Valenzano KJ, Walker K (2003) N-4- Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 306:387-393
139. Swanson DM, Dubin AE, Shah C, Nasser N, Chang L, Dax SL, Jetter M, Breitenbucher JG, Liu C, Mazur C, Lord B, Gonzales L, Hoey K, Rizzolio M, Bogenstaetter M, Codd EE, Lee DH, Zhang SP, Chaplan SR, Carruthers NI (2005) Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl) piperazine-1-carboxylic acid (5- trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J Med Chem 48:1857-1872
140. Brown BS, Keddy R, Zheng GZ, Schmidt RG, Koenig JR, McDonald HA, Bianchi BR, Honore P, Jarvis MF, Surowy CS, Polakowski JS, Marsh KC, Faltynek CR, Lee CH (2008) Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists. Bioorg Med Chem 16:8516-8525
141. Lappin SC, Randall AD, Gunthorpe MJ, Morisset V (2006) TRPV1 antagonist, SB-366791, inhibits glutamatergic synaptic transmission in rat spinal dorsal horn following peripheral inflammation. Eur J Pharmacol 540:73-81
142. Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM, Luis Hannan S, Lappin SC, Egerton J, Smith GD, Worby A, Howett L, Owen D, Nasir S, Davies CH, Thompson M, Wyman PA, Randall AD, Davis JB (2004) Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 46:133-149
143. Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, Wang J, Zhu D, Vanderah TW, Porreca F, Doherty EM, Norman MH, Wild KD, Bannon AW, Louis JC, Treanor JJ (2005) AMG9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin- 6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 313:474-484
144. Szallasi A, Cortright DN, Blum CA, Eid SR (2007) The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6: 357-372
145. Ognyanov VI, Balan C, Bannon AW, Bo Y, Dominguez C, Fotsch C, Gore VK, Klionsky L, Ma VV, Qian YX, Tamir R, Wang X, Xi N, Xu S, Zhu D, Gavva NR, Treanor JJ, Norman MH (2006) Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles. J Med Chem 49:3719-3742
146. Shishido Y, Jinno M, Ikeda T, Ito F, Sudo M, Makita N, Ohta A, Iki-Taki A, Ohmi T, Kanai Y, Tamura T, Shimojo M (2008) Synthesis of benzamide derivatives as TRPV1 antagonists. Bioorg Med Chem Lett 18:1072-1078
147. Westaway SM, Chung YK, Davis JB, Holland V, Jerman JC, Medhurst SJ, Rami HK, Stemp G, Stevens AJ, Thompson M,Winborn KY, Wright J (2006) N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1. Bioorg Med Chem Lett 16:4533-4536
148. Zheng X, Hodgetts KJ, Brielmann H, Hutchison A, Burkamp F, Brian Jones A, Blurton P, Clarkson R, Chandrasekhar J, Bakthavatchalam R, De Lombaert S, Crandall M, Cortright D, Blum CA (2006) From arylureas to biarylamides to aminoquinazolines: Discovery of a novel, potent TRPV1 antagonist. Bioorg Med Chem Lett 16:5217-5221
149. Culshaw AJ, Bevan S, Christiansen M, Copp P, Davis A, Davis C, Dyson A, Dziadulewicz EK, Edwards L, Eggelte H, Fox A, Gentry C, Groarke A, Hallett A, Hart TW, Hughes GA, Knights S, Kotsonis P, Lee W, Lyothier I, McBryde A, McIntyre P, Paloumbis G, Panesar M, Patel S, Seiler MP, Yaqoob M, Zimmermann K (2006) Identification and biological characterization of 6-aryl-7- isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain. J Med Chem 49:471-474
150. Crutchlow M (2009) Pharmacologic Inhibition of TRPV1 Impairs Sensation of Potentially Injurious Heat in Healthy Subjects. American Society for Clinical Pharmacology and Therapeutics (ASCPT) meeting
151. Harrop S (2006) Pain therapeutics-SMi's seventh annual conference. IDrugs 9:548-550
152. Gunthorpe MJ, Chizh BA (2009) Clinical development of TRPV1 antagonists: Targeting a pivotal point in the pain pathway. Drug Discov Today 14:56-67
153. Keith Bley Preclinical data were reported at the SMi Pain Therapeutics Meeting in London, UK, June 2006
154. DenneyWS (2009) 5th Modern Drug Discovery & Development Summit. Merck & Co, Inc, San Diego, CA
155. Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak A, Darling M, Gore A, Jang GR, Kesslak JP, Ni L, Norman MH, Palluconi G, Rose MJ, Salfi M, Tan E, Romanovsky AA, Banfield C, Davar G (2008) Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136:202-210
156. Samer RE TRP1 antaonists: Are they too hot to handle? Spring pain research conference cayman, United Kingdom 2008
157. Gavva NR (2008) Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol Sci 29:550-557
158. Lehto SG, Tamir R, Deng H, Klionsky L, Kuang R, Le A, Lee D, Louis JC, Magal E, Manning BH, Rubino J, Surapaneni S, Tamayo N, Wang T, Wang J, Wang J, Wang W, Youngblood B, Zhang M, Zhu D, Norman MH, Gavva NR (2008) Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2- (piperidin-1-yl)-4-(tri fluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 326:218-229
159. Garami A, Shimansky YP, Pakai E, Oliveira DL, Gavva NR, Romanovsky AA (2010) Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. J Neurosci 30:1435-1440
160. Seabrook GR, Sutton KG, Jarolimek W, Hollingworth GJ, Teague S, Webb J, Clark N, Boyce S, Kerby J, Ali Z, Chou M, Middleton R, Kaczorowski G, Jones AB (2002) Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy- 5-iodo-3-methoxyphenylacetate ester) iodo-resiniferatoxin. J Pharmacol Exp Ther 303: 1052-1060
161. Gavva NR, Klionsky L, Qu Y, Shi L, Tamir R, Edenson S, Zhang TJ, Viswanadhan VN, Toth A, Pearce LV, Vanderah TW, Porreca F, Blumberg PM, Lile J, Sun Y,Wild K, Louis JC, Treanor JJ (2004) Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem 279:20283-20295
162. Neelands TR, JarvisMF, Han P, Faltynek CR, Surowy CS (2005) Acidification of rat TRPV1 alters the kinetics of capsaicin responses. Mol Pain 1:28
163. Gavva NR, Bannon AW, Surapaneni S, Hovland DN Jr., Lehto SG, Gore A, Juan T, Deng H, Han B, Klionsky L, Kuang R, Le A, TamirR, Wang J, Youngblood B, Zhu D, Norman MH, Magal E, Treanor JJ, Louis JC (2007) The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci 27:3366-3374
164. Gavva NR, Bannon AW, Hovland DN Jr., Lehto SG, Klionsky L, Surapaneni S, Immke DC, Henley C, Arik L, Bak A, Davis J, Ernst N, Hever G, Kuang R, Shi L, Tamir R, Wang J, Wang W, Zajic G, Zhu D, Norman MH, Louis JC, Magal E, Treanor JJ (2007) Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther 323:128-137
165. Cuypers E, Yanagihara A, Karlsson E, Tytgat J (2006) Jellyfish and other cnidarian envenomations cause pain by affecting TRPV1 channels. FEBS Lett 580:5728-5732
166. Andreev YA, Kozlov SA, Koshelev SG, Ivanova EA, Monastyrnaya MM, Kozlovskaya EP, Grishin EV (2008) Analgesic compound from sea anemone Heteractis crispa is the first polypeptide inhibitor of vanilloid receptor 1 (TRPV1. J Biol Chem 283:23914-23921
167. Knotkova H, Pappagallo M, Szallasi A (2008) Capsaicin (TRPV1 Agonist) therapy for pain relief: Farewell or revival?. Clin J Pain 24:142-154
168. Reeves PJ, Callewaert N, Contreras R, Khorana HG (2002) Structure and function in rhodopsin: High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N- acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci U S A 99:13419-13424
169. Durocher Y, Perret S, Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30:E9
170. Cortright DN, Szallasi A (2009) TRP channels and pain. Curr Pharm Des 15:1736-1749
171. Yoshimura N, Kaiho Y, Miyazato M, Yunoki T, Tai C, Chancellor MB, Tyagi P (2008) Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol 377:437-448
172. Liddle RA (2007) The role of Transient Receptor Potential Vanilloid 1 (TRPV1) channels in pancreatitis. Biochim Biophys Acta 1772:869-878